RTHMWinter 2022Active☆Watch⊞Compare

RTHM is one of 233 Medical Devices companies tracked from San Francisco, CA, USA; Redwood City, CA, USA, on record since 2022. By capital raised it ranks in the long tail (ahead of 13% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst”

Simplifying complex illness care at scale

Current Description: RTHM provides virtual-first care for complex illness including Long COVID, ME/CFS, POTS, and mast cell activation. Many clinics focus on teaching patients how to better cope with symptoms, which is helpful, but we don’t stop there. We develop collaborations & partnerships so our patients access to the most promising testing and root-cause directed early therapies for their illness(es) with the goal of simplifying and streamlining the most efficient and effective clinical pathways so they can be scaled in the form of low cost online modules overseen remotely by clinicians. In conjunction with clinical care, RTHM operates a clinical lab and collects deep molecular data with robust clinical context to develop AI-powered diagnostics and better ways of predicting which treatments may work best for whom.

As reported in public records reported — not modeled.

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

No round amounts on record to chart.

No staged rounds to sequence.

Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Benchmarked against 233 companies in Medical Devices. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Raised more than 13% of sector peers (real $). Modeled value above 13% of peers (estimate).

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

RTHM is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

See where RTHM sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

If you work at RTHM, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.